New insulin method aims to protect kidneys in diabetes patients

NCT ID NCT07187479

Recruiting now Disease control Sponsor: Well Cell Global Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment called physiologic insulin resensitization (PIR) in 120 adults with advanced chronic kidney disease and type 2 diabetes. The goal is to see if PIR can improve kidney function better than standard care. Participants will be randomly assigned to receive either PIR or usual treatment, and their kidney health will be tracked over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetes mellitus end stage renal failure impaired renal function disease kidney disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (STAGES 4 AND 5) KIDNEY DISEASE TYPE 2 DIABETES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arizona Kidney Disease and Hypertension Center
RECRUITING

Phoenix, Arizona, 85027, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact